Researcher
Els Lierman
- Disciplines:Genetics, Systems biology, Molecular and cell biology
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Member
From1 Oct 2009 → 31 Dec 2014 - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Mar 2009 → 30 Sep 2009 - Department of Human Genetics (Department)
Member
From1 Oct 2005 → 28 Feb 2009
Projects
1 - 2 of 2
- Identification of recurrent genetic disorders in myeloproliferative neoplasms using an integrated genomics approach.From1 Jan 2011 → 30 Jun 2014Funding: Private funding of national origin - undefined
- Identification of recurrent genetic aberrations in myeloproliferative neoplasms using an integrated genomics approach.From1 Oct 2009 → 30 Sep 2012Funding: FWO fellowships
Publications
1 - 8 of 8
- Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel(2019)
Authors: Els Lierman, Sara Vander Borght
- ANALYSIS OF PHENOTYPE AND OUTCOME IN ESSENTIAL THROMBOCYTHEMIA WITH CALR AND JAK2 MUTATIONS(2015)
Authors: Carla Al Assaf, F Van Obbergh, J Billiet, Els Lierman, Timothy Devos, C Graux, A-S Hervent, Thomas Tousseyn, P De Paepe, P Papadopolous, et al.
Pages: 535 - 535 - Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFR alpha Fusion Kinase and of KIT(2011)
Authors: Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Debiec-Rychter, Peter Vandenberghe
Pages: 1645 - 1645 - Oncogenen en tumorsuppressorgenen(2011)
Authors: Peter Vandenberghe, Els Lierman, Karolien Beel, Nancy Boeckx, Caroline Brusselmans, Sarah Deleu, Tom Bos, Marc Bracke, Filip Lardon, Peter Vandenberghe, et al.
Pages: 83 - 117 - The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1 FGFR1 Fusion Detected In a Patient with T Lymphoblastic Leukemia/Lymphoma and t(7,8)(q22,p11)(2010)
Authors: Bartosz Wasag, Els Lierman, Peter Meeus, Jan Cools, Peter Vandenberghe
Pages: 1119 - 1119 - Downstream effectors of FIP1L1-PDGFRA as targets for therapy in chronic eosinophilic leukemia(2010)
Authors: Els Lierman, R Snoeckx, E Stover, Nathalie Berghen, P Bulens, P Erben, A Reiter, Peter Vandenberghe, Jan Cools
Pages: 165 - 165 - Identification and characterization of oncogenic tyrosine kinases and tyrosine kinase inhibitors(2009)
Authors: Els Lierman, Jan Cools, Peter Marynen
- FIP1L1-PDGFR alpha D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFR alpha T674I Eosinophilic Leukemia with Single Agent Sorafenib(2008)
Authors: Peter Vandenberghe, Els Lierman, Lucienne Michaux, Pascal Pierre, Peter Marynen, Jan Cools
Pages: 1279 - 1279